Kornimate/medical-research-clean huggingface dataset:
impact of "teaching the teachers" concept on global education and application of hepatocellular carcinoma diagnosis guidelines

Conditions: Hepatocellular Carcinoma

Summary: this study evaluates a concept called 'teaching the teachers' and whether it is helpful in disseminating guidelines on the national and international levels. "teaching the teachers" involves teaching the guidelines to experts who later teach the same guidelines to other radiologists, trainees, and physicians to assume the teacher's role and disseminate the guidelines and so on.

primary objectives: i. evaluate the magnitude of teaching of hepatocellular carcinoma (hcc) diagnostic guidelines after applying "teaching the teachers" concept. ii. assess the effect of "teaching the teachers" concept on application of guidelines in clinical practice. outline: participants complete surveys immediately after completion of a hcc diagnostic guideline webinar, monthly thereafter, and again at 6 months.

Eligibility criteria:
inclusion criteria: * physicians who finished radiology residency * radiologists with current or completed specialized training in abdominal imaging * radiologists with expertise in liver imaging with no minimum number of years of experience * radiologists working in academic, community, and governmental practices * radiologists with current practice in any country around the globe * radiologists with and without previous knowledge of hcc diagnosis guidelines (liver imaging reporting and data system \[li-rads\]) * radiologists with interest in education and/or teaching exclusion criteria: * physicians with no formal training in radiology * radiologists with no expertise in abdominal/liver imaging * current radiology residents * radiologists with no interest in education and/or teaching
study of casdatifan and cabozantinib versus placebo and cabozantinib in patients with advanced clear cell renal cell carcinoma

Conditions: Metastatic Clear Cell Renal Cell Carcinoma; Advanced Clear Cell Renal Cell Carcinoma

Summary: the purpose of the study is to evaluate the progression-free survival (pfs) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell renal cell carcinoma who have experienced progression on or after prior anti-pd-1 or anti-pd-l1 immunotherapy.


Eligibility criteria:
inclusion criteria: * unresectable and measurable locally advanced or metastatic renal cell carcinoma with a primary clear cell component. * a karnofsky performance status (kps) score ≥ 80% * at least 1 target lesion measurable by computed tomography/magnetic resonance imaging per recist 1.1, not within a field of prior radiation therapy. * adequate organ and marrow function, ≤ 72 hours prior to randomization. * women of childbearing potential (wocbp) must have a negative serum pregnancy test. exclusion criteria: * received prior treatment with a hif-2α inhibitor or cabozantinib. * other prior malignancy active within the previous year except for locally curable cancers that have been apparently cured. * clinically significant toxicities related to any prior anticancer treatment, or toxicities grade ≥ 3 per national cancer institute common terminology criteria for adverse events, version 5.0 (nci ctcae v5.0) regardless of relatedness to prior anticancer therapies. * uncontrolled or poorly controlled hypertension, as defined by a sustained blood pressure \> 140/90 mm hg on more than three antihypertensives * history of leptomeningeal disease or spinal cord compression. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: casdatifan metastatic clear cell renal cell carcinoma advanced clear cell renal cell carcinoma kidney cancer peak-1 ab521 ccrcc
prospective evaluation of the results of multidisciplinary follow-up after a transitional consultation for esophageal atresia

Conditions: Esophageal Atresia

Summary: a transition consultation for adult patients with esophageal atresia, involving medical and paramedical stakeholders, was set up at hôpital saint-louis in 2020. the aim of this initiative is to: 1. initiate adult medical, psychological and social follow-up; 2. empower these adults in their future care; 3. establish a personalized follow-up schedule. this project is the first to focus on post-traumatic stress disorder (ptsd) in young adults with esophageal atresia. a 3-year analysis of the somatic and psychosocial variables analyzed will confirm the validity of this initiative, and define its optimal contours for improving these patients' quality of life as adults.


Eligibility criteria:
inclusion criteria: * patients with esophageal atresia * aged 18 to 30 * followed at hôpital saint louis * informed and not opposed to the study * patients affiliated to a social security scheme exclusion criteria: * inability to answer questionnaires * patients under guardianship * patients under ame (aide médicale d'etat in france)

Keywords: esophageal atresia
non-invasive evaluation program for tips and follow up network 2 (neptun2)

Conditions: Portal Hypertension

Summary: evaluation of non-invasive prognostic parameters in patients receiving transjugular intrahepatic portosystemic shunt (tips) for complications of portal hypertension. patients are cared according to the local standardized follow up program. clinical and laboratory data from standard patient care are evaluated for potential prognostic value.

neptun consists of liver cirrhosis receiving transjugular intrahepatic portosystemic shunt (tips) at the department of internal medicine i, university of bonn, germany and receiving a structured routine evaluation and follow up program. the diagnosis of cirrhosis was based on clinical, hemodynamic and biochemical parameters, and ultrasound and/or biopsy criteria.

Eligibility criteria:
inclusion criteria: * insertion of tips according to guidelines exclusion criteria: * contraindication for tips

Keywords: transjugular intrahepatic portosystemic shunt (tips) non-invasive assessments transthoracic echocardiography (tte) with speckle-tracking computer tomography scan (ct-scan) magnetic resonance imaging (mri) circulating biomarkers electroencephalography (eeg) elastography
operative versus non-operative treatment of recalcitrant plantar fasciitis - a randomized study

Conditions: Plantar Fascitis; Surgical Treatment; Non-operative Treatment; Randomized Study

Summary: the purpose of the study is to examine whether patients with heel spurs for more than 6 months, who have been treated conservatively, have better effect of surgery than further conservative treatment. the study is performed as a randomized trial with the inclusion of 32 patients divided between open plantar fasciectomy and conservative treatment. the primary endpoint is self-reported-foot-and-ankle score (sefas-score) after 24 months. secondary endpoints includes: pain (visual analogue score) at first step, rest and activity after 3, 6, 12 and 24 months, sefas-score after 3, 6 og 12 months, changes in gait after 6 months (measured with gait-analysis). all endpoints are measured at inclusion. the power calculation is based on the assumption that surgical treatment gives an improvement in sefas-score of 10 points (sd 7.9) after 24 months when compared to conservative treatment together with an alpha-value of 5 % and a beta value of 90 %.


Eligibility criteria:
inclusion criteria: * age \> 18 years. * isolated plantar fasciitis through more than 6 months * ultrasonic verification of diagnosis (plantar fascia \>4 mm) * ability to follow the post-operative- and conservative plans * able to give informed consent. exclusion criteria: * previous surgical treatment of plantar fasciitis or surgery around the heel * rheumatic disease * diabetes * dementia * neuropathy * known alcohol abuse * pareses/paralysis of the affected extremity.
subconjunctiva bupivacaine as analgesia in intravitreal silicone oil removal

Conditions: Retinal Detachment

Summary: the study aimed to investigate the effectivity of bupivacaine 0,5% as post-operative analgesia in intravitreal silicone evacutaion surgery

approval from ethical committee of faculty of medicine universitas indonesia was acquired prior conducting the study. subjects were given informed consent before enrolling the study and randomized into two groups. intravenous (iv) cannule with ringer lactate fluid, non-invasive blood pressure monitor, electrocardiogram (ecg) and pulse-oxymetry were set on the subjects in the operation room. co-induction was done with midazolam 0,05 mg/kg and fentanyl 2 mcg/kg. induction was done with propofol 1-2 mg/kg, followed by laryngeal mask insertion facilitated by atracurium 0,5 mg/kg. maintenance was done with sevoflurane 1-2 vol%, o2:h2o = 1:2, flow 2 liter/minute. surgery started. after final stitching, group 1 received subconjunctival bupivacaine 0,5% 2,5ml in between stitches; group 2 received subconjunctival nacl 0,9% in between stitches. both groups received paracetamol 20 mg/kgbw iv as post-operative analgesics. hemodynamic, pain degree (using visual analog scale / vas), and nausea/vomiting incidence, and the time for first requested additional analgesia were recorded. data was analyzed using spss (statistical package for social scientist), for numerical data using unpaired t-test or mann-whitney-u test, for categorical data using chi-square test or fischer exact's test. data normality was tested by kolmogorov-smirnov test. significant value is p\<0.05.

Eligibility criteria:
inclusion criteria: * subjects aged 18-60 years old, with asa physical status i-ii and bmi 18,5-30 kg/m2 who were planned to do intravitreal silicone evacuation surgery. * subjects have been explained about the study, have agreed to enroll and have signed the informed consent form exclusion criteria: * subjects with history of post-operative chronic pain * subjects with history of pre-operative long term use of analgesic * subjects with history of local anesthetics allergy, pregnant subjects * subjects with ambulation operation * subjects with glaucoma or ocular hypertension * subjects with cognition dysfunction or communication disturbance * subjects with additional surgery other than silicone oil removal drop out criteria: * subjects with intraoperative complications (e.g. shock, anaphylactic reaction, seizures, severe respiratory disturbance) * subjects with post-operative intraocular pressure \> 22mmhg.

Keywords: bupivacaine intravitreal analgesia silicone oil removal retinal detachment subconjunctival
trial comparing radical radiotherapy to prostate only vs prostate and pelvic lymph nodes in intermediate and high risk prostate cancer

Conditions: Prostate Cancer

Summary: this phase ii randomized controlled study aims to compare the treatment results of intermediate and high risk prostate cancer patients treated with hormonal therapy and radical radiotherapy with or without pelvic lymph nodes in nci- cairo university.

study design : phase ii prospective randomized trial with 2 arms • prostate only (arm a) hypofractionated intensity modulated radiotherapy (imrt) to the prostate only to dose of 60gy/20fractions (3 gy per fraction) • prostate \& pelvic lymph nodes (arm b) hypofractionated intensity modulated radiotherapy (imrt) with elective pelvic nodes irradiation up to 44gy/20 fractions (2.2 gy per fraction) with a simultaneous integrated boost (sib) to the prostate to dose of 60gy/20fractions (3 gy per fraction)

Eligibility criteria:
inclusion criteria: * histologically-proven prostatic adenocarcinoma. * risk stratification from intermediate to very high risk will be included according to nccn guide lines september 5, 2019 version 4.2019: * intermediate risk: t2b or t2c and/or gs =7 and/or psa \>10-20. both the favorable intermediate (1 intermediate risk factor (irf) and grade group 1 or 2 and \<50% biopsy core positive) and unfavorable intermediate risk (2 or 3 irfs and/or grade group 3 and/or ≥50% biopsy cores positive) will be included. * high risk: t3a or psa \>20 or grade group 4 or 5, not very high risk. * very high risk: t3b-4, primary gleason pattern 5 or \>4 cores with grade group 4 or 5 * n stage: n0 * m stage: m0 * performance status: ps 0-2 exclusion criteria: * low risk prostate cancer * histologies other than adenocarcinoma * patients with significant comorbidities might affect treatment completion and follow up * previously received pelvic radiotherapy * patients with metastatic disease * poor performance status (ps ≥ 3)

Keywords: prostate cancer intermediate risk prostate cancer high risk prostate cancer hypofractionated radiotherapy pelvic lymph node irradiation
late phase 2 study of opc-12759 ophthalmic suspension

Conditions: Dry Eye Syndromes

Summary: the purpose of this study is to evaluate the dose-response of opc-12759 suspension in dry eye patients


Eligibility criteria:
inclusion criteria: 1. outpatient 2. subjective complaint of dry eye that has been present for minimum 20 months 3. ocular discomfort severity is moderate to severe 4. corneal - conjunctival damage is moderate to severe 5. unanesthetized schirmer's test score of 5mm/5minutes or less 6. best corrected visual acuity of 0.2 or better in both eyes exclusion criteria: 1. presence of anterior segment disease or disorder other than that associated with keratoconjunctivitis sicca 2. ocular hypertension patient or glaucoma patient with ophthalmic solution 3. anticipated use of any topically-instilled ocular medications or patients who cannot discontinue the use during the study 4. anticipated use of contact lens during the study 5. patient with punctal plug 6. any history of ocular surgery within 12 months 7. female patients who are pregnant, possibly pregnant or breast feeding 8. known hypersensitivity to any component of the study drug or procedural medications 9. receipt of any investigational product within 4 months

Keywords: dry eye syndromes opc-12759
a safety and efficacy trial of multiple dosing regimens of abt-719 for the prevention of acute kidney injury in subjects undergoing high risk surgery

Conditions: Cardiothoracic Surgery; Vascular Surgery

Summary: this study will evaluate the safety and efficacy of abt-719 in patients undergoing high risk major surgery.


Eligibility criteria:
inclusion criteria: - patients undergoing high risk major surgery in subjects with cardiovascular disease who are at risk of aki. exclusion criteria: * ongoing or recent history of sepsis * has recent documented acute kidney injury. * subject is scheduled to have a total or partial nephrectomy.

Keywords: high risk surgery acute kidney injury
extension study of abbv-8e12 in patients with progressive supranuclear palsy (psp) who completed study c2n-8e12-ww-104

Conditions: Progressive Supranuclear Palsy (PSP)

Summary: the purpose of this study is to assess the long-term safety and tolerability of abbv-8e12 in subjects with progressive supranuclear palsy (psp).


Eligibility criteria:
inclusion criteria: * subject completed study c2n-8e12-ww-104 (nct02494024) * subject was not eligible to enroll in study m15-562 (nct02985879) exclusion criteria: * subject weighs less than 35 kg at screening * subject has any contraindication or inability to tolerate brain mri * subject has any significant change in his/her medical condition that could interfere with the subject's participation in the study, could place the subject at increased risk, or could confound interpretation of study results
multicenter study to perioperative chemotherapy for resectable adenocarcinoma in gastric cancer

Conditions: Gastric Cancer

Summary: the rationale of the neo-flot-trial consists of an intensification of the neoadjuvant treatment. this strategy is based upon the clear advantage of perioperative treatment and the fact, that in former trials adjuvant treatment could only be given in half of the patients (cunningham 2006, boige 2007). in this study neoadjuvant chemotherapy is applied during a period of 12 weeks with an interim staging after 6 weeks.due to the favourable efficacy and toxicity data the flot-regimen was chosen for the neoadjuvant treatment consisting of oxaliplatin, docetaxel, folinic acid and 5-fluorouracil (al-batran 2008). postoperative treatment according to the results of the magic trail is not part of the trail and is given at the responsibility of the participating centres.


Eligibility criteria:
inclusion criteria: * histologically confirmed adenocarcinoma of the gastroesophageal junction (aeg i-iii) or gastric adenocarcinoma (every t, n+ or t3/t4, nx, m0) * written informed consent * age ≥ 18 years * expected operability * ecog ≤ 2 * exclusion of peritoneal metastasis * adequate hematological, renal, cardiac and hepatic function * effective contraception exclusion criteria: * prior chemotherapy or radiotherapy of the adenocarcinoma of the gastroesophageal junction (aeg i-iii) or gastric adenocarcinoma * not histologically confirmed primary tumor * distant metastasis, local relapse * known hypersensitivity for 5-fluorouracil, leucovorin, oxaliplatin or docetaxel * known dihydropyrimidin-dehydrogenase (dpd) - deficiency * peripheral polyneuropathy ≥ grade ii (nci-ctcae, version 3.0) * myocardial infarction in the last 3 months, cardiac insufficiency grade ii-iv (nyha) * severe comorbidity or acute infections * pregnancy or breast feeding * insufficient contraception * participation in another clinical trial (simultaneously or 30 days prior to enrollment) * malignancy \<5 years (except: carcinoma in situ of the cervix uteri or adequately treated basalioma of the skin) * lack of legal capacity
effect of visual retraining after stroke

Conditions: Vision Loss Partial; Vision; Loss, Both Eyes; Hemianopia Homonymous; Hemianopia; Quadrantanopia; Stroke, Ischemic; Stroke - Occipital Infarction; Cortical Blindness

Summary: this project is intended to collect data using standard clinical tests and psychophysics to quantify the effect of visual cortical damage on the structure of the residual visual system, visual perception, spatial awareness, and brain function. the investigators will also assess the effect of intensive visual retraining on the residual visual system, processing of visual information and the use of such information in real-world situations following damage. this research is intended to improve our understanding of the consequences of permanent visual system damage in humans, of methods that can be used to reverse visual loss, and of brain mechanisms by which visual recovery is achieved.


Eligibility criteria:
cortically blind subjects inclusion: * between 21 and 80 years of age * residents of the united states or canada * unilateral stroke or stroke-like damage to primary visual cortex or its immediate afferent white matter sustained within the specified age range (21-75 years) * reliable visual field defects in both eyes as measured by humphrey, maia, goldmann, and/or equivalent perimetry, large enough to enclose a 5-deg diameter visual stimulus. * able to fixate on visual targets reliably for 1000ms * must have a home computer (desktop or laptop) and reliable internet access * willing, able, and competent to provide informed consent * normal cognitive abilities, able to understand written and oral instructions in english, and competent and responsible adults in order to complete the visual training at home, independently, as instructed, for several months. exclusion: * past or present eye disease interfering with visual acuity * bcva worse than 20/40 in either eye * damage to the dorsal lateral geniculate nucleus * diffuse whole brain degenerative processes * history of traumatic brain injury * any other brain damage deemed by study staff to potentially interfere with training ability or outcome measures * documented history of drug/alcohol abuse * currently taking neuroactive medications which would impact training, as determined by pi * presence of cognitive or seizure disorders * one-sided attentional neglect * subjects who lack the competence or are otherwise unable to perform the visual training exercises as directed. control subjects (n = 50) inclusion: * between 21 and 80 years of age * report no history of neurological disorder. * competent and responsible, as determined by the principal investigator. exclusion: * presence of damage to the visual system * presence of an active disease process involving their nervous system. * cognitive or seizure disorders * best corrected visual acuity worse than 20/40 in either eye * presence of vision field loss from ocular disease or disorder
mediterranean style diet and low glycemic responses

Conditions: Insulin Sensitivity

Summary: the aim of this study is to evaluate whether a mediterranean diet rich in pasta and other starchy foods with a (low-gi), as compared with a similar mediterranean diet containing very little pasta and based on starchy foods with a (hi-gi) is able to reduce insulin and glucose concentrations during a prolonged test study meal.

the overall aim of this study is to evaluate whether a mediterranean diet rich in pasta and other starchy foods with a low glycemic response (low-gi), as compared with a similar mediterranean diet containing very little pasta and based on starchy foods with a high glycemic response (hi-gi) is able to reduce insulin and glucose concentrations during a prolonged test study meal.

Eligibility criteria:
inclusion criteria: * • bmi 25-37 kg/m2 with a waist circumference \> 102 cm (males) or \> 88 cm (females) and one additional feature of metabolic syndrome according to atpiii \[1\], including blood pressure \> 130/85 or treatment, fasting plasma glucose \>100mg/dl, fasting triglycerides \>150 mg/dl, hdl cholesterol \< 40 mg/dl (males) or 50 mg/dl (females), * weight stable (± 3 kg in previous 3 mo); * no acute illness; and non-diabetic. exclusion criteria: * age \ 69years; * fasting triglycerides ≥400 mg/dl; * fasting cholesterol \>240 mg/dl or low-density lipoprotein cholesterol\>160 mg/dl * fasting glucose \>126 mg/dl, * systolic blood pressure \>160 mmhg, diastolic blood pressure \>100 mmhg * a bmi \>37 kg/m2, weight changes during the previous 3 months (greater than ± 3 kg), * stable intensive physical activity regimen during the previous 3 months (\>3 h/wk of moderate or high intensity exercise, resistance or aerobic training). * cardiovascular events (myocardial infarction or stroke) during the 6 months prior to the study; * renal and liver failure (creatinine \>1.7 mg/dl and alt/ast \>2 times than normal values, respectively); * anaemia (hb \<12 g/dl); * diabetes mellitus. * if you are pregnant
hemostasis during hypospadias surgery

Conditions: Hypospadias Repair

Summary: a comparison between the two hemostatic methods of hypospadias repairing operation, in terms of early and mid-term (up to 6 months) failure rate (wound dehiscence and urethral stricture needing reoperation) between the two groups: group a) diluted epinephrine injection, group b) tourniquet application in children


Eligibility criteria:
inclusion criteria: - age under 15 hypospadiasis ( distal, midshaft, proximal) exclusion criteria: - bleeding tendency penoscrotal hypospadiasis other method

Keywords: hypospadias dehiscence urethral stricture side effects